Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

Dave Ricks  | November 9, 2020

Lilly’s purpose – to make life better – has never been more important, and we are bringing the full force of our scientific and medical expertise to attack the novel coronavirus around the world.

Lilly advanced the fight into a new era with the start of human studies of the world’s first therapies specifically designed to treat COVID-19 – antibodies engineered for their potential to neutralize the disease.

Our scientists rapidly developed the first antibody in just three months after AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified it from a blood sample taken from one of the first US COVID-19 patients to recover.

We're proud to announce that, after rigorous scientific review of our BLAZE-1 data, the U.S. Food and Drug Administration (FDA) has granted our antibody treatment Emergency Use Authorization. This authorization allows us to make a treatment available for high-risk patients with recently diagnosed, mild to moderate COVID-19 – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic.